10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2023

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                                         to                                         

Commission File Number 000-50009

PACIFIC HEALTH CARE ORGANIZATION, INC.
(Exact name of registrant as specified in its charter)
Utah	87-0285238
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
19800 MacArthur Boulevard, Suites 306 & 307
Irvine, California	92612
(Address of principal executive offices)	(Zip Code)

(949) 721-8272

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for any shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

As of November 14, 2023, the registrant had 12,800,000 shares of common stock, par value $0.001, issued and outstanding. 

PACIFIC HEALTH CARE ORGANIZATION, INC.

FORM 10-Q

TABLE OF CONTENTS

		Page
PART I — FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements		3
	(Unaudited) Balance Sheets as of September 30, 2023 and December 31, 2022	3
	(Unaudited) Statements of Operations for the Three and Nine Months Ended September 30, 2023 and 2022	4
	(Unaudited) Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2023 and 2022	5
	(Unaudited) Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		10
Item 3. Quantitative and Qualitative Disclosures about Market Risk		24
Item 4. Controls and Procedures		24
PART II — OTHER INFORMATION
Item 1A. Risk Factors		25
Item 6. Exhibits		25
Signatures		26

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Pacific Health Care Organization, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

	September 30,			December 31,
	2023			2022
ASSETS
Current Assets
Cash	$	2,359,882		$	2,036,432
Investments		7,769,403			8,748,435
Accounts receivable, net of allowance of $9,302 and $7,807		832,826			934,990
Receivable – other		-			3,000
Prepaid income tax		82,000			-
Prepaid expenses		189,445			175,355
Total current assets		11,233,556			11,898,212
Property and Equipment, net
Computer equipment		259,334			256,500
Furniture and fixtures		21,620			20,328
Total property and equipment		280,954			276,828
Less: accumulated depreciation and amortization		(207,075	)		(179,423	)
Net property and equipment		73,879			97,405
Operating lease right-of-use assets, net		-			50,137
Other assets		7,110			6,602
Total Assets	$	11,314,545		$	12,052,356
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable	$	121,925		$	263,022
Accrued expenses		314,687			332,551
Income tax payable		193,258			3,132
Dividends payable		109,333			37,000
Operating lease liabilities, current portion		-			39,620
Unearned revenue		37,315			33,544
Total current liabilities		776,518			708,869
Long Term Liabilities
Operating lease liabilities, long term portion		-			10,517
Deferred tax liabilities		15,679			15,679
Total Liabilities	$	792,197		$	735,065
Commitments and Contingencies		-			-
Stockholders’ Equity
Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized of which 40,000 shares designated as Series A preferred and 16,000 shares issued and outstanding		16			16
Common stock, $0.001 par value, 800,000,000 shares authorized, 12,800,000 shares issued and outstanding		12,800			12,800
Additional paid-in capital		416,057			416,057
Retained earnings		10,093,475			10,888,418
Total stockholders’ equity		10,522,348			11,317,291
Total Liabilities and Stockholders’ Equity	$	11,314,545		$	12,052,356

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Pacific Health Care Organization, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	For three months ended September 30,						For nine months ended September 30,
	2023			2022			2023			2022
Revenues:
HCO	$	373,280		$	354,913		$	945,759		$	985,192
MPN		132,403			128,297			392,789			422,227
Medical bill review		90,988			99,418			266,030			333,310
Medical case management		292,195			384,657			922,273			1,218,077
Utilization review		451,167			443,049			1,360,998			1,220,941
Other		36,006			43,663			99,727			102,084
Total revenues		1,376,039			1,453,997			3,987,576			4,281,831
Expenses:
Depreciation		8,936			9,661			27,652			23,153
Bad debt provision		1,265			(5,520	)		2,429			(737	)
Consulting fees		56,418			56,148			173,235			166,309
Salaries and wages		638,288			699,026			1,927,044			2,018,638
Professional fees		89,677			76,065			263,880			222,703
Insurance		81,003			79,974			229,599			238,851
Outsource service fees		180,579			156,677			529,861			433,275
Data maintenance		4,524			2,898			69,278			59,400
General and administrative		168,344			112,135			390,019			418,079
Total expenses		1,229,034			1,187,064			3,612,997			3,579,671
Income from operations		147,005			266,933			374,579			702,160
Other income (expense)
Interest income		102,017			-			301,991			-
Total other income (expense)		102,017			-			301,991			-
Income before taxes		249,022			266,933			676,570			702,160
Income tax provision		(69,901	)		(74,928	)		(189,913	)		(197,096	)
Net income	$	179,121		$	192,005		$	486,657		$	505,064
Basic earnings per share:
Earnings per share amount	$	0.01		$	0.02		$	0.04		$	0.04
Basic common shares outstanding		12,800,000			12,800,000			12,800,000			12,800,000
Fully diluted earnings per share:
Earnings per share amount	$	0.01		$	0.01		$	0.04		$	0.04
Fully diluted common shares outstanding		12,816,000			12,816,000			12,816,000			12,816,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Pacific Health Care Organization, Inc.

Condensed Consolidated Statements of Stockholders' Equity

(Unaudited)

	Convertible Preferred Stock				Common Stock				Additional Paid-in		Retained			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Earnings			Equity
Balances at December 31, 2021		16,000	$	16		12,800,000	$	12,800	$	416,057	$	10,395,532		$	10,824,405
Net Income		-		-		-		-		-		188,535			188,535
Balances at March 31, 2022		16,000	$	16		12,800,000	$	12,800	$	416,057	$	10,584,067		$	11,012,940
Net Income		-		-		-		-		-		124,524			124,524
Balances at June 30, 2022		16,000	$	16		12,800,000	$	12,800	$	416,057	$	10,708,591		$	11,137,464
Net Income		-		-		-		-		-		192,005			192,005
Balances at September 30, 2022		16,000	$	16		12,800,000	$	12,800	$	416,057	$	10,900,596		$	11,329,469
Balances at December 31, 2022		16,000	$	16		12,800,000	$	12,800	$	416,057	$	10,888,418		$	11,317,291
Net Income		-		-		-		-		-		131,109			131,109
Balances at March 31, 2023		16,000	$	16		12,800,000	$	12,800	$	416,057	$	11,019,527		$	11,448,400
Net Income		-		-		-		-		-		176,427			176,427
Common stock cash dividends paid		-		-		-		-		-		(1,280,000	)		(1,280,000	)
Preferred stock cash dividends paid		-		-		-		-		-		(1,600	)		(1,600	)
Balances at June 30, 2023		16,000	$	16		12,800,000	$	12,800	$	416,057	$	9,914,354		$	10,343,227
Net Income		-		-		-		-		-		179,121			179,121
Balances at September 30, 2023		16,000	$	16		12,800,000	$	12,800	$	416,057	$	10,093,475		$	10,522,348

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Pacific Health Care Organization, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended September 30,
	2023			2022
Cash flows from operating activities:
Net income	$	486,657		$	505,064
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		27,652			23,153
Bad debt provision		2,429			(737	)
Noncash interest on investments		(126,422	)		-
Changes in operating assets and liabilities:
Decrease in accounts receivable		99,735			64,657
Decrease in deferred rent assets		-			10,055
Increase in prepaid expenses		(14,090	)		(60,359	)
Decrease in income taxes receivable		-			19,779
Decrease in receivable - other		3,000			-
Increase in prepaid income tax		(82,000	)		-
(Increase) decrease in other assets		(508	)		20,186
(Decrease) increase in accounts payable		(141,097	)		44,438
Decrease in accrued expenses		(17,864	)		(68,221	)
Increase in unearned revenue		3,771			6,979
Increase in income tax payable		190,126			7,316
Net cash provided by operating activities		431,389			572,310
Cash flows from investing activities:
Proceeds from investments		8,748,435			-
Purchase of investments		(7,642,981	)		-
Purchase of furniture and office equipment		(4,126	)		(17,619	)
Net cash provided by (used in) investing activities		1,101,328			(17,619	)
Cash flows from financing activities:
Issuance of cash dividend		(1,209,267	)		-
Net cash used in financing activities		(1,209,267	)		-
Increase in cash		323,450			554,691
Cash at beginning of period	$	2,036,432		$	10,085,372
Cash at end of period	$	2,359,882		$	10,640,063
Supplemental cash flow information
Cash paid for:
Interest	$	-		$	-
Income taxes	$	82,000		$	170,000
Non-cash investing and financing activities:
Dividends payable	$	72,333		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

Pacific Health Care Organization, Inc.

Notes to Condensed Consolidated Financial Statements

For the Nine Months Ended September 30, 2023

(Unaudited)

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”) and in accordance with accounting principles generally accepted in the United States (“GAAP”). Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted in accordance with GAAP rules and regulations. The information furnished in these unaudited condensed consolidated financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect both the recorded values of assets and liabilities at the date of the condensed consolidated financial statements and the revenues recognized and expenses incurred during the reporting period. These estimates and assumptions affect the Company’s recognition of deferred expenses, bad debts, income taxes, the carrying value of its long-lived assets and its provision for certain contingencies. The reasonableness of these estimates and assumptions is evaluated continually based on a combination of historical and other information that comes to the Company’s attention that may vary its outlook for the future. While management believes the disclosures and information presented are adequate to make the information not misleading, the Company recommends these unaudited condensed consolidated financial statements be read in conjunction with its audited financial statements and notes thereto included in its annual report on Form 10-K for the year ended December 31, 2022. Operating results for the nine-month period ended September 30, 2023, are not necessarily indicative of the results to be expected for the year ending December 31, 2023.

Principles of Consolidation — The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.

Basis of Accounting — The Company uses the accrual method of accounting in accordance with accounting principles generally accepted in the United States for the periods ended September 30, 2023 and 2022.

Revenue Recognition — The Company recognizes revenue in accordance with ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The core principle underlying Topic 606 is that the Company will recognize revenue to represent the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer.

ASC 606 requires the use of a five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. Revenues are generated as services are provided to the customer based on the sales price agreed and collected. The Company recognizes revenue as the time is worked or as units of production are completed, which is when the revenue is earned and realized. Labor costs are recognized as the costs are incurred.

The Company derives its revenue from the sale of services offered through its HCOs, MPNs, medical bill review, medical case management, employee advocate, utilization review, workers’ compensation carve-outs, and Medicare set-aside. These services are billed individually as separate components to our customers. Services from which we generate fees include monthly and/or annual HCO and/or MPN administration, claim and network access, medical bill review, medical case management, employee advocate, utilization review, workers’ compensation carve-outs, and Medicare set-aside.

7

Pacific Health Care Organization, Inc.

Notes to Condensed Consolidated Financial Statements

For the Nine Months Ended September 30, 2023

(Unaudited)

The Company enters arrangements for bundled managed care, standalone services, or add-on ancillary services which include various units of accounting such as network solutions and patient management, and managed care. Such elements are considered separate units of accounting due to each element having value to the customer on a stand-alone basis and are billed separately. The selling price for each unit of accounting is determined using the contract price. When the Company’s customers purchase several services, the pricing of the service sold is generally the same as if the services were sold on an individual basis. Revenue is recognized as the work is performed in accordance with the Company’s customer contracts. Based upon the nature of the Company’s services, bundled managed care elements are generally delivered in the same accounting period. The Company recognizes revenue for patient management services ratably over the life of the customer contract. Based upon prior experience in managed care, the Company estimates the deferral amount from when the customer’s claim is received to when the customer contract expires. Advance payments from subscribers and billings made in advance are recorded on the balance sheet as deferred revenue.

Accounts Receivable and Bad Debt Allowance – In the normal course of business the Company extends credit to its customers on a short-term basis. Although the credit risk associated with these customers is minimal, the Company routinely reviews its accounts receivable balances and makes provisions for doubtful accounts. The Company ages its receivables by invoice date. Management reviews bad debt reserves quarterly and reserves specific accounts as warranted or sets up a general reserve based on amounts over 90 days past due. When an account is deemed uncollectible, the Company charges off the receivable against the bad debt reserve. A considerable amount of judgment is required in assessing the realization of these receivables including the current creditworthiness of each customer and related aging of the past-due balances, including any billing disputes. To assess the collectability of these receivables, the Company performs ongoing credit evaluations of its customers’ financial condition. Through these evaluations, the Company may become aware of situations where a customer may not be able to meet its financial obligations due to deterioration of its financial viability, credit rating or bankruptcy. The allowance for doubtful accounts is based on the best information available to the Company and is reevaluated and adjusted as additional information is received. The Company evaluates the allowance based on historical write-off experience, the size of the individual customer balances, past-due amounts, and the overall national economy. At September 30, 2023 and December 31, 2022, bad debt reserves of $9,302 and $7,807, respectively, were maintained in a general reserve for certain balances over 90 days past due and for potentially uncollectible accounts.

The percentages of the amounts due from major customers to total accounts receivable as of September 30, 2023 and December 31, 2022, are as follows:

	9/30/2023			12/31/2022
Customer A		34	%		18	%
Customer B		12	%		7	%
Customer C		8	%		24	%

Significant Customers - The Company provides services to insurers, third party administrators, self-administered employers, municipalities, and other industries. The Company is able to provide its full range of services to virtually any size employer in the state of California. Outside the state of California, the Company is able to provide utilization review, medical bill review and medical case management services.

During the periods ended September 30, 2023 and 2022, the Company had three customers, respectively, that individually accounted for more than 10% of its total sales. The following table sets forth the percentages of total sales attributable to those customers during those periods:

	9/30/2023			9/30/2022
Customer A		24	%		28	%
Customer B		10	%		10	%
Customer C		10	%		9	%

Leases - The Company follows the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company elected to exclude from its balance sheet the recognition of leases having a term of 12 months or less. Lease expense is recognized on a straight-line basis over the lease term. See Note 2 for further information regarding the Company’s leases.

8

Pacific Health Care Organization, Inc.

Notes to Condensed Consolidated Financial Statements

For the Nine Months Ended September 30, 2023

(Unaudited)

NOTE 2 - OPERATING LEASES

On April 1, 2022, the Company moved office locations from 1201 Dove Street, Suite 300 in Newport Beach, California to 19800 MacArthur Boulevard, Suites 306 & 307, in Irvine, California. This lease was to expire as of March 31, 2023, but was renewed on December 10, 2022, for an additional 12-months, with a new expiration of March 31, 2024. The Company elected to exclude from its balance sheet the recognition of leases having a term of 12 months or less.

Lease expenses were $10,714 and $9,903 during the three-month periods ended September 30, 2023 and 2022, respectively; and $31,407 and $19,806 during the nine-month periods ended September 30, 2023 and 2022, respectively.

NOTE 3 - SHAREHOLDERS’ EQUITY

During the quarter ended June 30, 2023, our board of directors declared a special one-time cash dividend of $0.10 per share on each share of Company common stock outstanding at the record date of June 5, 2023. Pursuant to the rights provided in the Designation of Rights, Privileges and Preferences of Series A Preferred Stock dated December 27, 2019, holders of the Company’s Series A Preferred Stock participated in the dividend payment based on the number of shares of Series A Preferred Stock held on the record date. On the record date, June 5, 2023, we had 12,800,000 shares of common stock and 16,000 shares of Series A Preferred stock issued and outstanding.

As of September 30, 2023, we issued $1,281,600 in dividends with $72,333 of that amount remaining payable. This payable has been accrued and included in the dividends payable on the balance sheet.

NOTE 4 - SUBSEQUENT EVENTS

In accordance with ASC 855-10 Company management reviewed all material events through the date of issuance and has determined that there are no material subsequent events to report.

9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Throughout this quarterly report, unless the context indicates otherwise, the terms, “we,” “us,” “our” or the “Company” refer to Pacific Health Care Organization, Inc., (“PHCO”) and our wholly-owned subsidiaries Medex Healthcare, Inc. (“Medex”), Medex Managed Care, Inc. (“MMC”) and Medex Medical Management, Inc. (“MMM”), and, where applicable, our former subsidiaries Industrial Resolutions Coalition (“IRC”) Medex Legal Support, Inc. (“MLS”) and Pacific Medical Holding Company, Inc. (“PMHC”).

All statements other than statements of historical fact included herein and in the documents incorporated by reference in this quarterly report on Form 10-Q (this “quarterly report”), if any, including without limitation, statements regarding our future financial position or results of operations, business strategy, potential acquisitions, budgets, projected costs, and plans and objectives of management for future operations, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “foresee,” “future,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” and other similar expressions and their negatives.

Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties, many of which may be beyond our control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof, and actual results could differ materially as a result of various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from anticipated results or events:

● competition within our industry, including competition from much larger competitors;

● reductions in worker’s compensation claims or the demand for our services, from whatever source;

● cost reduction efforts by our existing and prospective customers;

● our ability to retain existing customers and to attract new customers;

● delays, reductions, or cancellations of contracts we have previously entered;

● the loss, ineffective management, malfunction (including those resulting from cybersecurity incidences and breaches), or increased costs of third-party-provided technologies and services on which our operations rely;

● the loss of or inability to obtain adequate insurance coverage;

● cybersecurity incidences and breaches, and other software system failures, and the imposition of laws imposing costly cybersecurity and data protection compliance;

● business combinations involving our customers or competitors;

● economic and labor market conditions generally and in the industries in which we and our customers participate, including the effects resulting from economic recessions, financial sector turmoil, international conflicts, and rising domestic inflation and related economic policy responses;

● the impacts on our business of COVID-19, including the reduction of our customers’ workforces as a result of a variety of COVID-19-related causes, as well as government mandates and impacts on the workers’ compensation industry, the businesses of our customers and on the economy generally;

● legislative and regulatory requirements or changes which could render our services less competitive or obsolete; and

● our failure to successfully develop new services and/or products either organically or through acquisition, or to anticipate current or prospective customers’ needs.

For more detailed information about particular risk factors related to us and our business, see Item 1A Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “Commission”) on March 31, 2023 (our “Annual Report”).

We operate in a competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

10

One should not place undue reliance on forward-looking statements. Forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management and apply only as of the date of this quarterly report or the respective dates of the documents from which it incorporates by reference. Neither we nor any other person assumes any responsibility for the accuracy or completeness of forward-looking statements. Further, except to the extent required by law, we undertake no obligations to update or revise any forward-looking statements, whether as a result of new information, future events, or a change in events, conditions, circumstances, or assumptions underlying such statements, or otherwise. We may also make additional forward-looking statements from time to time. Any subsequent forward-looking statements, whether written or oral, made by us or on our behalf, are also expressly qualified by these cautionary statements.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes contained elsewhere in this quarterly report and in our other filings with the Commission.

Overview

We incorporated under the laws of the state of Utah in April 1970, under the name Clear Air, Inc. We changed our name to Pacific Health Care Organization, Inc., in January 2001. In February 2001, we acquired Medex, a California corporation organized in March 1994, in a share for share exchange. Medex is in the business of managing and administering both Health Care Organizations (“HCOs”) and Medical Provider Networks (“MPNs”) in the state of California. In August 2001, we formed IRC, a California corporation, as a wholly owned subsidiary of PHCO. Prior to closing IRC, IRC oversaw and managed our workers’ compensation carve-outs services. In June 2010, we acquired MLS, a Nevada corporation incorporated in September 2009. Prior to closing MLS, MLS offered lien representation services and Medicare set-aside services (“MSA”). In March 2011, we incorporated MMC, a Nevada corporation, as a wholly owned subsidiary of the Company. MMC oversees and manages the Company’s utilization review and bill review services. In February 2012, we incorporated MMM, a Nevada corporation, as a wholly owned subsidiary of the Company. MMM is responsible for overseeing and managing medical case management services. In October 2018, we incorporated PMHC, a Nevada corporation, as a wholly owned subsidiary of the Company to act as a holding company for future potential acquisitions.

In October 2021, we terminated the existence of IRC, MLS and PMHC and wound up those subsidiaries in an effort to simplify business procedures, bookkeeping and administrative structure, eliminate duplicative functions, and reduce costs. The business, assets, liabilities, and services of those entities were transferred to PHCO or its other subsidiaries. Medex now offers our workers’ compensation carve-out services previously provided by IRC and Medicare set-aside previously managed by MLS. As of the third quarter of 2023, we have discontinued lien representation services due to lack of customer demand and resources.

Business of the Company

We offer an integrated and layered array of complementary business solutions that enable our customers to better manage their employee workers’ compensation-related healthcare administration costs. We are constantly looking for ways to expand the suite of services we can provide our customers, either through strategic acquisitions or organic development.

Our business objective is to deliver value to our customers by reducing their workers’ compensation-related medical claims expense in a manner that will assure that injured employees receive high quality healthcare that allows them to recover from an injury and return to gainful employment without undue delay. According to studies conducted by auditing bodies on behalf of the California Division of Workers’ Compensation, (“DWC”) the two most significant cost drivers for workers’ compensation are claims frequency and longer than average treatment duration. Our services focus on ensuring timely medical treatment to reduce the claim duration and medical treatment costs.

Our services include providing customers access to our HCOs and MPNs. We also provide medical bill review, medical case management, employee advocate services, utilization review, workers’ compensation carve-outs, and Medicare set-aside services. Complementary to these services, we also provide expert witness testimony. We offer our services as a bundled solution, as standalone services, or as add-on services.

Our core services focus on reducing medical treatment costs by enabling our customers to have control and oversight of the medical treatment of their injured employees to ensure treatment is timely and appropriate. This control is primarily obtained by participation in our HCOs or one of our MPNs. Through Medex, we hold two of the total of four licenses issued by the state of California to establish and manage HCOs within the state of California. We hold several government-issued licenses to operate medical provider networks. We also hold approvals issued by the state of California to act as an MPN and currently administer 21 MPNs. Our HCO and MPN programs provide our customers with provider networks within which the customer has some ability to direct the administration of the claim. This is designed to decrease the incidence of fraudulent claims and disability awards and ensure injured employees receive necessary vocational rehabilitation and training. Our medical bill and utilization review services provide oversight of medical billing and treatment requests, and our medical case management and employee advocate services keep workers’ compensation claims progressing to a resolution and assures treatment plans are aligned from a medical perspective.

11

Our customers include self-administered employers, insurers, third party administrators, municipalities, and others. Our principal customers are companies with operations located in the state of California where the cost of workers’ compensation insurance is a critical problem for employers, though we process medical bill reviews, utilization reviews and provide medical case management in several other states. Our provider networks, which are located only in California, are composed of providers experienced in treating worker injuries.

Our business generally has a long sales cycle, typically eight months or more. Once we have established a customer relationship and enrolled the employees of our employer customers, we anticipate our revenue to adjust with the growth or retraction of our customers’ employee headcount. Throughout the year, we also expect to add new customers while others terminate for a variety of reasons. The reasons for termination vary but include when a customer switches to an insurance carrier or third party administrator that uses a different workers’ compensation administration vendor, or when our contract ends with state and local governments.

Key trends affecting results of operations

During the nine months ended September 30, 2023 and 2022, COVID-19 continued to impact the businesses of our customers and our results of operations. For example, in the first quarter of 2022, our customers had a relatively large increase in COVID-19 workers’ compensation claims due to the seasonality of the illness and as the economy opened back up and employees returned to their workplaces. Our HCO customers’ industries generally have a higher risk of exposure to COVID-19 and thus reported a greater number of COVID-19 claims. As a result, COVID-19 claims remained elevated in the first nine months of 2022. Our MPN customers, whose industries were at a relatively lower risk for COVID-19 exposure had a large increase in reported COVID-19 claims in the first quarter of 2022 but began to return to pre-pandemic levels during the second quarter of 2022. During the first three quarters of 2023, COVID-19 claims have remained low and we have realized minimal related revenues, as a result. We anticipate that revenues related to COVID-19 will remain low through the remainder of 2023.

During 2022, the increased volume of COVID-19 workers’ compensation claims resulted in temporary increases in our revenues generated from claim network and medical case management fees, particularly during the first quarter of 2022. However, that trend began reversing during the second quarter of 2022 as the severity and frequency of the illness declined and California Sick Paid Leave “CSPSL” ended paid time off for COVID-19 related illnesses, which we believe also has contributed to lower reporting of COVID-19 claims.

The relative decline in COVID-19 workers’ compensation claims resulted in lower revenues generated from HCO and MPN claim network and medical case management fees when comparing the three- and nine-month periods of 2023 with 2022. We do not expect further material declines in COVID-19 workers’ compensation claims and related revenues as the current level of new COVID-19 claims is minimal.

During the third quarter of 2023, we saw an increase in the number of employees enrolled in our HCO and MPN programs. The enrollment numbers in our HCO and MPN programs generally correlate with economic conditions and the size and activities of our customers’ workforce. If economic conditions become challenging, including from the effects of inflationary pressures, elevated interest rates, and challenging labor market conditions, our customers may reduce their workforce, in which case we would expect a decline in the number of employees enrolled in our HCO and MPN programs in future periods and in related revenues.

During the fourth quarter of 2022 and through the first quarter of 2023, we experienced difficulties transitioning to a new software vendor for our utilization review and medical case management services. Throughout the software transition, our automated processes had to be performed manually, which caused delays in providing services and invoicing our customers, reduced productivity and resulted in additional outsourcing costs. Our net income was adversely impacted in the first quarter of 2023 as a result of the interruptions and costs associated with the software transition. However, during the third quarter of 2023 the issues were resolved. As of the date of this quarterly report, the delayed invoicing problems have been addressed and much of the related outstanding accounts receivable has decreased.

As previously disclosed in our Annual Report, Fortra, LLC, the third-party vendor that provides the GoAnywhere managed file transfer as a service system (MFTaaS), experienced a data security incident that affected many of Fortra’s customers, including the Company. As of the date of this quarterly report, this incident has not caused a material interruption of our business operations. We are in the process of providing appropriate notifications to the individuals affected by the incident, as well as to various State Attorneys General. We have incurred expenses, and may incur in the future expenses and losses, related to this incident, some of which may not be covered by cyber liability insurance. Further, because of the ongoing nature of the effects of this incident and current unknowns, an estimate of the impact on our business, results of operations and other potential liabilities cannot be made.

12

Revenue

We derive revenue from fees charged for access to our HCO and MPN provider networks, claim network fees, HCO/MPN network administration, medical bill review, medical case management and employee advocate, utilization review, Medicare set-asides, and network access.

HCO

HCO revenue is generated from fees charged to our employer customers for claim network fees to access our HCO networks, employee enrollment into our HCO program, program administration, custom network fees, annual and new hire notifications, and fees for other ancillary services they may select.

MPN

Like HCO revenue, MPN revenue is generated from fees charged to our employer customers for claim network fees to access our MPN networks, custom network fees, MPN notifications, and program administration. Unlike HCOs, from which we derive revenues from annual and new hire notification fees, MPNs do not require annual and new hire notifications and as such we do not generate related revenues. Rather, MPN notification revenues are limited to the required notices to an injured employee at the time the employer is notified by the injured employee that an injury occurred.

Medical bill review

California and many other states have established fee schedules for the maximum allowable fees payable under workers’ compensation for a variety of procedures performed by medical providers. Many procedures, however, are not covered under the fee schedules, such as hospital bills, which still require review and negotiation. Medical bill review involves analyzing medical provider services and equipment billing to ascertain proper reimbursement. Our medical bill review services include coding review and re-bundling, confirming that the services are customary and reasonable, fee schedule compliance, out-of-network bill review, pharmacy review, and preferred provider organization repricing arrangements. Our medical bill review services can result in significant savings for our customers. Revenue for medical bill reviews is generated based on a set fee per medical bill reviewed and a percentage of savings of the preferred provider organization (PPO) discounts. Hospital bill review services generate revenue on a percentage of savings off of the hospital bill, usually with a negotiated cap.

Medical case management

Medical case management oversees the injured employees’ medical treatment to ensure that it progresses to a resolution and assures treatment plans are aligned from a medical perspective. Medical oversight is a collaborative process that assesses, evaluates, coordinates, implements and monitors medical treatment plans and the options and services required to meet an injured worker’s health needs. Our medical case management services are performed by nurses who are credentialed by the state and have expertise in various clinical areas and backgrounds in workers’ compensation matters. We work to manage the number of nurses in our program to maintain our ratio of claims per nurse at a level that ensures timely and appropriate medical care is given to the injured worker and facilitates faster claim closures for our customers. We also offer employee advocate services, which is similar to medical case management in that it utilizes our medical case managers who provide similar services; however, the medical case manager is an advocate of the employee. We generate revenue from these services when we receive a workers’ compensation claim and a medical case manager is assigned to oversee the injured workers’ medical treatment, with billing based on the number of hours a medical case manager works on the claim.

Utilization review

Utilization review is the review of medical treatment requests by providers to provide a safeguard for employers and injured employees against unnecessary or inappropriate medical treatment from the perspective of medical necessity, quality of care, appropriateness of decision-making, and timeliness of treatment. Its purpose is to reduce employer liability for medical costs that are not medically appropriate or approved by the relevant medical and legal authorities and the payor. We generate revenue when we receive a referral for a request for authorization of treatment from a claims adjuster. We bill by the number of treatment requests and the level of expertise of the reviewer required to approve, modify, or deny the request.

Other

Other revenue consists of revenue derived from network access fees charged for network access for preferred provider organizations, ancillary legal support services, Medicare set-aside and workers’ compensation carve-out services.

13

The following table sets forth, for the three- and nine-month periods ended September 30, 2023 and 2022, respectively, the percentage each revenue item identified in our unaudited condensed consolidated financial statements contributed to total revenues during the respective period.

	For the three months ended						For the nine months ended
	September 30,						September 30,
	2023			2022			2023			2022
HCO		27	%		24	%		24	%		23	%
MPN		10	%		9	%		10	%		10	%
Medical bill review		6	%		7	%		7	%		8	%
Medical case management		21	%		26	%		23	%		28	%
Utilization review		33	%		31	%		34	%		29	%
Other		3	%		3	%		2	%		2	%

Expense

Consulting fees

Consulting fees include fees we pay to third parties for IT, marketing, lobbying, and in-house legal services related to the various services we offer.

Salaries and wages

Salaries and wages reflect employment-related compensation we pay to our employees, payroll processing, payroll taxes and commissions.

Professional fees

Professional fees include fees we pay to third parties to provide medical consulting, field medical case management, and board of directors’ fees for board meetings, as well as legal, accounting, and other professional services fees.

Insurance

Insurance expenses are comprised primarily of health insurance benefits offered to our employees, directors’ and officers’ liability insurance, cyber security, workers’ compensation coverage and business liability coverage.

Outsource service fees

Outsource service fees consist of costs incurred by our subsidiaries by partially outsourcing utilization review, medical bill review, administrative services for medical case management and HCO, and Medicare set-aside services, and typically tend to fluctuate in correlation with customer demand for those services.

Data maintenance fees

Data maintenance fees include fees we pay to a third party to process HCO employee enrollments and MPN notices. HCO employee enrollment and MPN notification fees fluctuate throughout the year because of the varied timing of customer enrollment into our HCO program, the number of employees our customers have in their workforce, the number of new hires throughout the year, and the number of new workers’ compensation claims.

General and administrative

General and administrative expenses consist primarily of office rent, advertising, dues and subscriptions, equipment/repairs, IT enhancement, licenses and permits, telephone, office supplies, parking, postage, printing and reproduction, miscellaneous expenses, shareholders’ expense, charity – cash contribution, auto expenses, bank charges, education, travel and entertainment, and vacation expense.

14

The following table sets forth, for the three- and nine-month periods ended September 30, 2023 and 2022, respectively, the percentage each expense item identified in our unaudited condensed consolidated financial statements contributed to total expenses during the respective period.

	For the three months ended						For the nine months ended
	September 30,						September 30,
	2023			2022			2023			2022
Depreciation		-	%		1	%		1	%		1	%
Bad debt provision		-	%		-	%		-	%		-	%
Consulting fees		5	%		5	%		5	%		4	%
Salaries and wages		52	%		59	%		53	%		56	%
Professional fees		7	%		6	%		7	%		6	%
Insurance		7	%		7	%		6	%		7	%
Outsource service fees		15	%		13	%		15	%		12	%
Data maintenance fees		-	%		-	%		2	%		2	%
General and administrative		14	%		9	%		11	%		12	%

Results of Operations

Comparison of the three months ended September 30, 2023 and 2022

The following represents selected components of our consolidated results of operations for the three-month periods ended September 30, 2023 and 2022, respectively, together with changes from period-to-period:

	For three months ended September 30,
	2023			2022			Amount Change			% Change
Revenues:
HCO	$	373,280		$	354,913		$	18,367			5	%
MPN		132,403			128,297			4,106			3	%
Medical bill review		90,988			99,418			(8,430	)		(8	%)
Medical case management		292,195			384,657			(92,462	)		(24	%)
Utilization review		451,167			443,049			8,118			2	%
Other		36,006			43,663			(7,657	)		(18	%)
Total revenues		1,376,039			1,453,997			(77,958	)		(5	%)
Expenses:
Depreciation		8,936			9,661			(725	)		(8	%)
Bad debt provision		1,265			(5,520	)		6,785			123	%
Consulting fees		56,418			56,148		270				-	%
Salaries and wages		638,288			699,026			(60,738	)		(9	%)
Professional fees		89,677			76,065			13,612			18	%
Insurance		81,003			79,974			1,029			1	%
Outsource service fees		180,579			156,677			23,902			15	%
Data maintenance		4,524			2,898			1,626			56	%
General and administrative		168,344			112,135			56,209			50	%
Total expenses		1,229,034			1,187,064			41,970			4	%
Income from operations		147,005			266,933			(119,928	)		(45	%)
Other income (expense)
Interest income		102,017			-			102,017			100	%
Total other income (expense)		102,017			-			102,017			100	%
Income before taxes		249,022			266,933			(17,911	)		(7	%)
Income tax provision		(69,901	)		(74,928	)		5,027			(7	%)
Net income	$	179,121		$	192,005		$	(12,884	)		(7	%)

15

Revenue

HCO

During the three-month period ended September 30, 2023, HCO revenue increased 5% compared to the same period in the prior year. The increase in HCO revenue was primarily due to an increased number of monthly and annual HCO enrollees and related administration and notification fees. The increase was partially offset by decreases in claim network fees for COVID-19 claims as they were minimal in the three-month period ended September 30, 2023, compared to the same period in the prior year; as well as decreases in non-COVID-19 claim network fees.

MPN

MPN revenue for the three-month period ended September 30, 2023, increased 3% compared to the same period in the prior year. The increase in revenue was largely attributable to an increase in monthly MPN enrollees and related administration fees. The increase in MPN revenue was partially offset by decreases in the number of claims from which we generate claim network fee revenue.

Medical bill review

During the three-month period ended September 30, 2023, medical bill review revenue decreased 8% compared to the same period in the prior year. The decrease was primarily due to the loss of two customers in the second quarter of 2023 and fewer medical bills reviewed. The decrease was partially offset by the addition of a new customer in the fourth quarter of 2022.

Medical case management

During the three-month period ended September 30, 2023, medical case management revenue decreased 24% compared to the same period in the prior year. The decrease was attributable to a decline in COVID and non-COVID-19 claims from existing customers. During the pandemic, some of our customers opted to have COVID-19 claims assigned to a medical case manager, regardless of severity of the illness, and the trend continued into the third quarter of 2022. Since the third quarter of 2022, due largely to the severity and frequency of COVID-19 claims declining, our customers have stopped requiring a medical case manager to be assigned to those claims, which has adversely impacted medical case management revenues. The decrease in medical case management revenue was partially offset by increases in revenue generated from our employee advocate services.

Utilization review

During the three-month period ended September 30, 2023, utilization review revenue increased 2% compared to the same period in the prior year. The increase in revenue was due to increases in utilization review referrals from existing customers and the addition of a new customer in the fourth quarter of 2022, partially offset by a decrease stemming from the loss of a customer in the second quarter of 2023.

Other

Other revenue for the three-month period ended September 30, 2023, decreased 18% compared to the same period in the prior year. The decrease was mainly attributable to a decrease in the number of referrals for Medicare set-aside. The decrease was partially offset by an increase in network access fee revenue from increased access to our network by preferred provider organizations. 

Expenses

Total expenses for the three-month period ended September 30, 2023, increased 4% compared to the same period in the prior year. The increase was primarily attributable to increases in general and administrative, outsource service fees, professional fees, and bad debt provision, which were partially offset by decreases in salaries and wages.

Depreciation

During the three-month period ended September 30, 2023, depreciation expenses decreased 8% compared to the same period in the prior year. The decrease was primarily due to certain computer equipment fully depreciating.

16

Bad debt provision

During the three-month period ended September 30, 2023, bad debt provision increased 123% compared to the same period in the prior year stemming from invoice delays related to our utilization review and medical case management software transition, which impacted our ability to collect payments.

Salaries and wages

During the three-month period ended September 30, 2023, salaries and wages decreased 9% compared to the same period in the prior year. The decrease was due to us having fewer employees and was partially offset by an increase in wages and salaries for our existing employees.

Professional fees

During the three-month period ended September 30, 2023, professional fees increased 18% compared to the same period in the prior year. The increase in professional fees was primarily the result of additional legal and accounting services, partially offset by decreases in other professional services and field medical case management fees. The increase in legal services was related to legal fees stemming from a bill dispute and the data security incident during 2023, and the increase in accounting services was related to an employee retention credit, which is a refundable tax credit for businesses and tax-exempt organizations that had employees and were affected during the COVID-19 pandemic.

Outsource service fees

During the three-month period ended September 30, 2023, outsource service fees increased 15% compared to the same period in the prior year. The increase in outsource service fees was primarily attributable to an increased demand for our utilization review and HCO services, the provision of which utilizes outsourced services. The increase was partially offset by decreases in the outsourced services for Medicare set-asides. Our outsourcing and related fees will continue to correspond with the level of medical bill review, utilization review, enrollees in our HCO program, certain field medical case management and Medicare set-aside services.

Data maintenance

During the three-month period ended September 30, 2023, data maintenance fees increased 56% compared to the same period in the prior year. The increase in data maintenance fees was due to increases in our customers’ employee counts for enrollment in our HCO and MPN programs, which have corresponding data maintenance needs.

General and administrative

General and administrative expenses increased 50% during the three-month period ended September 30, 2023 compared to the same period in the prior year. The increase was primarily due to increases in dues and subscriptions, vacation expenses, advertising and marketing, and IT enhancement. The increase was partially offset by decreases in licenses and permits and other general and administrative expenses.

Income from Operations

During the three-month period ended September 30, 2023, income from operations was $147,005, compared to $266,933 during the same period in 2022, a 45% decrease. This $119,928 decrease was the result of a $77,958 decrease in revenues and a $41,970 increase in expenses.

Other Income (Expense)

On June 9, 2023, we reinvested $7,642,981 into U.S. Treasury bills that will mature on December 7, 2023. During the third quarter ended in 2023, we had noncash interest income of $102,017 from our investment in U.S. Treasury bills, whereas we had no interest income during the same period of 2022. We anticipate continued other income from the interest earned on our current investment in U.S. Treasury bills.

Income Tax Provision

We realized a $69,901, or 7%, decrease in our income tax provision during the three-month period ended September 30, 2023, compared to the same period in the prior year. The decrease in income tax provision was attributable to a 5% decrease in revenues, which was partially offset by a 4% increase in total expenses and a 100% increase in interest income.

17

Net Income

During the three-month period ended September 30, 2023, we realized a 5% decrease in total revenues, a 4% increase in total expenses, a 100% increase in noncash interest income, and a 7% decrease in our provision for income tax when compared to the same period in the prior year. The increase in noncash interest income of $102,017 was the result of interest earned on our U.S. Treasury bill investments during the three-month period ended September 30, 2023, whereas we had no interest income during the same period of 2022. The increase in interest income did not entirely offset the decrease in income from operations, and we realized a decrease of $12,884, or 7%, in net income during the three-month period ended September 30, 2023, compared to the three-month period ended September 30, 2022. We expect to have continued lower revenues for the remaining quarter of 2023 when compared to the same period in 2022, due to the continued effects of our loss of customers, but that interest income from our investments will continue to partially offset any decreases in revenue. We anticipate that this trend will continue to materially impact our net income during the balance of fiscal 2023 and potentially into 2024, although we anticipate that the losses will be partially offset by the expansion of our employee advocate program and interest earned on our investments.

Comparison of nine months ended September 30, 2023 and 2022

The following represents selected components of our consolidated results of operations for the nine-month periods ended September 30, 2023 and 2022, respectively, together with changes from period-to-period:

	For nine months ended September 30,
	2023			2022			Amount Change			% Change
Revenues:
HCO	$	945,759		$	985,192		$	(39,433	)		(4	%)
MPN		392,789			422,227			(29,438	)		(7	%)
Medical bill review		266,030			333,310			(67,280	)		(20	%)
Medical case management		922,273			1,218,077			(295,804	)		(24	%)
Utilization review		1,360,998			1,220,941			140,057			11	%
Other		99,727			102,084			(2,357	)		(2	%)
Total revenues		3,987,576			4,281,831			(294,255	)		(7	%)
Expenses:
Depreciation		27,652			23,153			4,499			19	%
Bad debt provision		2,429			(737	)		3,166			430	%
Consulting fees		173,235			166,309			6,926			4	%
Salaries and wages		1,927,044			2,018,638			(91,594	)		(5	%)
Professional fees		263,880			222,703			41,177			18	%
Insurance		229,599			238,851			(9,252	)		(4	%)
Outsource service fees		529,861			433,275			96,586			22	%
Data maintenance		69,278			59,400			9,878			17	%
General and administrative		390,019			418,079			(28,060	)		(7	%)
Total expenses		3,612,997			3,579,671			33,326			1	%
Income from operations		374,579			702,160			(327,581	)		(47	%)
Other income (expense)
Interest Income		301,991			-			301,991			100	%
Total other income (expense)		301,991			-			301,991			100	%
Income before taxes		676,570			702,160			(25,590	)		(4	%)
Income tax provision		(189,913	)		(197,096	)		7,183			(4	%)
Net income	$	486,657		$	505,064		$	(18,407	)		(4	%)

18

HCO

During the nine-month period ended September 30, 2023, HCO revenue decreased 4% compared to the same period in the prior year. Due to the nature of their industries, our HCO customers had an increased frequency of COVID-19 claims during 2022, and as a result related revenue remained higher through the end of the third quarter of 2022. The decrease in HCO revenue was primarily due to a reduction in HCO claim network fees from fewer COVID-19 claims, which was partially offset by increases in HCO enrollment and notification fees related to an increase in the number of enrolled employees, when compared to the same period in the prior year.

MPN

During the nine-month period ended September 30, 2023, MPN revenue decreased 7% compared to the same period in the prior year. The decrease in MPN revenue was primarily attributable to the decrease in COVID-19 claims which generate MPN claim network fees. The decrease was partially offset by increases in the number of enrollees into our monthly MPN program.

Medical bill review

During the nine-month period ended September 30, 2023, medical bill review revenue decreased 20% compared to the same period in the prior year. The decrease was primarily due to fewer hospital and non-hospital bills reviewed for customers and the loss of two customers in the second quarter of 2023. The decrease was partially offset by the addition of a new customer in the fourth quarter of 2022.

Medical case management

During the nine-month period ended September 30, 2023, medical case management revenue decreased 24% compared to the same period in the prior year. The decrease was attributable to a decline in COVID-19 and non-COVID-19 claims from existing customers. During the pandemic, some of our customers opted to have COVID-19 claims assigned to a medical case manager, regardless of severity of the illness, and the trend continued into the third quarter of 2022. Since the third quarter of 2022, due largely to the severity and frequency of COVID-19 claims declining, our customers have stopped requiring a medical case manager to be assigned to those claims, which has adversely impacted medical case management revenues. The decrease in medical case management revenue was partially offset by increases in revenue generated from our employee advocate services.

Utilization review

During the nine-month period ended September 30, 2023, utilization review revenue increased 11% compared to the same period in the prior year. The increase in revenue was due to increases in utilization review referrals from existing customers and the addition of a new customer in the fourth quarter of 2022, partially offset by a decrease in utilization review referrals stemming from the loss of a customer in the second quarter of 2023.

Other

Other revenue for the nine-month period ended September 30, 2023, decreased 2% compared to the same period in the prior year. The decrease was mainly attributable to decreases in the number of referrals for Medicare set-aside. The decrease was partially offset by an increase in network access fee revenue from increased access to our network by preferred provider organizations.

Expenses

Total expenses for the nine-month period ended September 30, 2023, increased 1%, compared to the same period in the prior year. The increase was primarily attributable to increases in outsource service fees, professional fees, data maintenance, consulting fees, depreciation, and bad debt provision, which were partially offset by decreases in salaries & wages, general and administrative, and insurance.

19

Depreciation

During the nine-month period ended September 30, 2023, depreciation expenses increased 19% compared to the same period in the prior year. The increase was primarily due to depreciating fixed assets that were purchased in the last twelve months.

Bad debt provision

During the nine-month period ended September 30, 2023, bad debt provision expenses increased 430% compared to the same period in the prior year stemming from invoice delays related to our utilization review and medical case management software transition, which impacted our ability to collect payments, and an abrupt closure of one of our customers in the second quarter of 2023. 

Salaries and wages

During the nine-month period ended September 30, 2023, salaries and wages decreased 5% compared to the same period in the prior year. The decrease was due to us having fewer employees and was partially offset by an increase in wages and salaries for our existing employees.

Professional fees

During the nine-month period ended September 30, 2023, professional fees increased 18% compared to the same period in the prior year. The increase in professional fees was primarily the result of additional legal, field medical case management and accounting services, partially offset by decreases in other professional services. The increase in legal services was related to legal fees stemming from a bill dispute and the data security incident during 2023, and the increase in accounting services was related to an employee retention credit, which is a refundable tax credit for businesses and tax-exempt organizations that had employees and were affected during the COVID-19 pandemic.

Outsource service fees

During the nine-month period ended September 30, 2023, outsource service fees increased 22% compared to the same period in the prior year. The increase in outsource service fees was primarily attributable to increased demand for our utilization review, HCO, field medical case management, and Medicare set-aside services, the provision of which utilize outsourced services. The increase was partially offset by decreases in the outsourced services for medical bill review due to fewer medical bills reviewed. Our outsourcing and related fees will continue to correspond with the level of medical bill review, enrollees in our HCO, utilization review, certain field medical case management and Medicare set-aside services.

Data maintenance

During the nine-month period ended September 30, 2023, data maintenance fees increased 17% compared to the same period in the prior year. The increase in data maintenance fees was due to increases in our customers’ employee counts for enrollment in our HCO and MPN programs, which have corresponding data maintenance needs.

General and administrative

General and administrative expenses decreased by 7% during the nine-month period ended September 30, 2023 compared to the same period in the prior year. The decrease was primarily due to decreases in office rent, licenses and permits, telephone, and a one-time credit for IT enhancement as a result of resolving a bill dispute. The decrease was partially offset by increases in dues and subscriptions, vacation expenses, advertising and marketing, auto expenses, and other general and administrative expenses.

Income from Operations

During the nine-month period ended September 30, 2023, income from operations was $374,579, compared to $702,160 during the same period in 2022, a 47% decrease. This $327,581 decrease was the result of a $294,255 decrease in revenues and $33,326 increase in expenses.

20

Other Income (Expense)

During the nine-month period ended September 30, 2023, we had interest income of $301,991 from our investment in U.S. Treasury bills which matured on June 8, 2023 and interest income on U.S. Treasury bills that will mature on December 7, 2023.  The total interest earned in U.S. Treasury bills that matured on June 8, 2023 was $202,693 and was recognized during the second quarter of 2023. On June 9, 2023, we reinvested $7,642,981 in U.S. Treasury bills with a maturity date of December 7, 2023. The noncash interest on the U.S. Treasury bills purchased on June 9, 2023 was $126,422. We anticipate continued net income from the interest earned on our current investment in U.S. Treasury bills.

Income Tax Provision

We realized a decrease in our income tax provision of $7,183, or 4%, during the nine-month period ended September 30, 2023, compared to the same period in the prior year. The decrease in income tax provision was attributable to a 7% decrease in total revenues, which was partially offset by a 1% increase in total expenses and 100% increase in interest income.

Net Income

During the nine-month period ended September 30, 2023, we realized a 7% decrease in total revenues, a 1% increase in total expenses, a 100% increase in interest income and a 4% decrease in our provision for income tax when compared to the same period in the prior year. Decreases in revenues were offset by cash and noncash interest income of $301,991 from the interest earned on our U.S. Treasury bill investments during the nine-month period ended September 30, 2023. The increase in interest income did not entirely offset the decrease in income from operations, and we realized net income of $486,657, a 4% decrease in net income during the nine-month period ended September 30, 2023, compared to the same period in the prior year. We expect to have continued lower revenues for the remaining quarter of 2023 when compared to the same period in 2022 as a result of fewer COVID-19 claims and the loss of two customers, but that interest income from our investments will continue to partially offset any decreases in revenue. We expect that the loss of customers will materially impact our net income during the balance of fiscal 2023 and potentially into 2024, although we anticipate the losses will be partially offset by the expansion of our employee advocate services and interest earned on our investments.

Liquidity and Capital Resources

Liquidity is a measurement of our ability to meet our potential cash requirements for general business purposes. We consistently monitor our liquidity and financial position and take actions management believes are in the best interest of the Company and its shareholders to ensure the long-term financial viability of the Company. Historically, we have realized positive cash flows from operating activities, which, coupled with positive reserves of cash on hand, have been used to fund our operating expenses and obligations.

We have focused on reducing other operating expenses while maintaining our ability to provide the high-quality services to which our customers are accustomed. For example, in April 2022 our office lease in Newport Beach, California expired, and we entered into a 12-month lease for a smaller office space in Irvine, California. In December 2022, we renewed the new office space lease for an additional 12-month period which will expire March 31, 2024. As a result of relocating to a smaller office and continuing to have our employees work remotely, we have decreased the operating costs for office expenses, but have utilized some of those savings to enhance our IT security, as well as other IT enhancements.

We currently have planned certain capital expenditures to replace our laptops and ancillary devices due to their age and as part of our ongoing continuity plan. We anticipate investing activities will continue throughout 2023 as we replace aging software, computer equipment, and further enhance our IT security. We anticipate these costs will be significant, but believe we have adequate capital on hand to cover these expenses. We do not anticipate these expenditures will require us to seek outside sources of funding.

During the nine-month period ended September 30, 2023, we realized net income of $486,657, as a result of interest income from our investment in U.S. Treasury bills and income from operations during that period. As of September 30, 2023, we had $2,359,882 in cash on hand compared to $2,036,432 at December 31, 2022. The $323,450 increase in cash on hand was largely due to decreases in accounts receivable from customers paying invoices that were outstanding due to problems in transitioning our operational software and decreases in accounts payable related to the resolution of a bill dispute with a vendor. Management currently believes that absent (i) the loss of a major customer, (ii) additional software issues, (iii) increases in or sustained inflation, (iv) an increased or longer-term downturn in the general economy, or (v) any unanticipated further adverse impacts related to COVID-19, cash on hand and anticipated revenues from operations will be sufficient to cover our operating expenses for at least the next twelve months.

21

Cash Flow

For the nine-month period ended September 30, 2023, cash was primarily used for the issuance of the one-time cash dividend in June 2023 and to fund operations. During the nine-month period ended September 30, 2023, cash used in financing activities consisted of a one-time cash dividend paid in June 2023. We had a net increase in cash of $323,450 and $554,691, during the nine-month periods ended September 30, 2023 and 2022, respectively. See below for additional discussion and analysis of cash flow.

	For the nine months ended September 30,
	2023 (unaudited)			2022 (unaudited)
Net cash provided by operating activities	$	431,389		$	572,310
Net cash provided by (used in) investing activities		1,101,328			(17,619	)
Net cash used in financing activities		(1,209,267	)		-
Net increase in cash	$	323,450		$	554,691

During the nine-month period ended September 30, 2023, net cash provided by operating activities was $431,389, and $572,310 in the same period of 2022. The decrease in cash flow from operations during the first three quarters of 2023 was the result of realizing lower net income coupled with increases in income tax payable, accounts payable, prepaid income tax, prepaid expenses, unearned revenue, and other assets, partially offset by decreases in accounts receivable, accrued expenses, receivable – other, taxes receivable, and deferred rent assets. A large portion of the decrease in accounts receivable was due to customers paying the invoices that were outstanding due to problems in transitioning our operational software for utilization review and medical case management.

Net cash provided by investing activities was $1,101,328 during the nine-month period ended September 30, 2023, and $17,619 used in investing activities during the nine-month period ended September 30, 2022. The increase in net cash provided by investing activities was due to the U.S. Treasury bills maturing, partially offset by the investment in new U.S. Treasury bills. We recognized interest of $202,693 for interest earned on our investments during the nine-month period ended September 30, 2023. We expect net cash used in investing activities to increase through 2023 and 2024 as we plan to update our current computer equipment.

During the nine-month period ended September 30, 2023, net cash used in financing activities was $1,209,267, which was the net amount of the one-time cash dividend paid in June 2023 of $1,281,600 and $72,333 in dividends payable. We did not engage in any financing activities during the nine-month period ended September 30, 2022.

Off-Balance Sheet Financing Arrangements

As of September 30, 2023, we had no off-balance sheet financing arrangements.

Inflation

We experience pricing pressures in the form of competitive pricing. Insurance carriers and third-party administrators compete against us for customers by offering bundled claims administration services with their own managed care services at a lower rate. We are also impacted by rising costs for certain inflation-sensitive operating expenses such as labor and employee benefits and facility leases. We believe that these impacts can be material to our revenues or net income. Some of our customers are public entities which contract with us at a fixed price for the term of the contract. Increases in labor and employee benefits can reduce our profit margin over the term of these contracts. See also “the effects of inflation may have a disproportionate impact on our business” of Item 1A Risk Factor of our Annual Report.

Critical Accounting Estimates

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Application of these principles requires us to make estimates, assumptions, and judgments that affect the amounts reported in our consolidated financial statements and accompanying notes. Because of the inherent uncertainty in making estimates and judgments, actual results could differ from our estimates and judgments. Our critical accounting policies are disclosed in Note 2, Significant Accounting Policies, of the Notes to Consolidated Financial Statements in our Annual Report and Note 1 and Note 2 to the Notes to the Condensed Consolidated Financial Statements in this quarterly report.

22

We continually evaluate our accounting estimates and judgments and base our estimates and judgments on historical experience and various other factors that we believe to be reasonable under the circumstances. Our critical accounting estimates include leases, allowance for uncollectible accounts, and income taxes, and are discussed in more detail below. Such accounting estimates require the most subjective or complex judgments by us, often as a result of the need to make assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates.

Leases: We determine if an arrangement includes a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term; and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable.

Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, we utilize our incremental borrowing rate to discount lease payments, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Allowance for Uncollectible Accounts: We determine our allowance for uncollectible accounts by considering several factors, including the length of time trade accounts receivable are past due, our previous loss history, the customers’ current ability to pay its obligation to us, and the condition of the general economy and the industry as a whole. We write off accounts receivable when they become uncollectible.

We must make significant judgments and estimates in determining contractual and bad debt allowances in any accounting period. One significant uncertainty inherent in our analysis is whether our past experience will be indicative of future periods. Although we consider future projections when estimating contractual and bad debt allowances, we ultimately make our decisions based on the best information available to us at the time the decision is made. Adverse changes in general economic conditions or trends in reimbursement amounts for our services could affect our contractual and bad debt allowance estimates, collection of accounts receivable, cash flows, and results of operations. At September 30, 2023, three customers accounted for 10% or more of accounts receivable compared to three customers at December 31, 2022.

Accounting for Income Taxes: We record a tax provision for the anticipated tax consequences of our reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. We record a valuation allowance, if necessary, to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Management believes it is more likely than not that forecasted income, including income that may be generated as a result of certain tax planning strategies, together with future reversals of existing taxable temporary differences, will be sufficient to fully recover the deferred tax assets. In the event we determine all, or part of the net deferred tax assets are not realizable in the future, we will make an adjustment to the valuation allowance that would be charged to earnings in the period such determination is made. In addition, the calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on our financial condition and operating results. The significant assumptions and estimates described above are important contributors to our ultimate effective tax rate each year.

23

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Smaller reporting companies are not required to provide this information.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, which are controls and other procedures that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Our management, under the supervision and with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023, the end of the period covered by this quarterly report, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2023, that materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

24

PART II. OTHER INFORMATION

Item 1A. Risk Factors

Management does not believe there have been any material changes to the risk factors listed in Part I, Item 1A, Risk Factors in our Annual Report.

Item 6. Exhibits

Exhibits. The following exhibits are filed or furnished, as applicable, as part of this quarterly report:

Exhibit Number	Title of Document
Exhibit 31.1	Certification of Principal Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1	Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 101	Pursuant to Rules 405 and 406 of Regulation S-T, the following information is formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Unaudited Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022, (ii) the Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2023 and 2022, (iii) the Unaudited Condensed Consolidated Statements of Stockholder’s Equity for the Three and Nine Months Ended September 30, 2023 and 2022, (iv) the Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022, (v) Notes to the Unaudited Condensed Consolidated Financial Statements, and (vi) the cover page.
Exhibit 104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this quarterly report to be signed on its behalf by the undersigned, thereunto duly authorized.

		PACIFIC HEALTH CARE ORGANIZATION, INC.
Date:	November 14, 2023	/s/ Tom Kubota
		Tom Kubota Chief Executive Officer
Date:	November 14, 2023	/s/ Kristina Kubota
		Kristina Kubota Chief Financial Officer

26

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Tom Kubota, certify that:

1) I have reviewed this quarterly report on Form 10-Q of Pacific Health Care Organization, Inc.:

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

(a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal controls over financial reporting; and

5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2023	By:	/s/ Tom Kubota
		Tom Kubota Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Kristina Kubota, certify that:

1) I have reviewed this quarterly report on Form 10-Q of Pacific Health Care Organization, Inc.:

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

(a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal controls over financial reporting; and

5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2023	By:	/s/ Kristina Kubota
		Kristina Kubota Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Pacific Health Care Organization, Inc. (the “Company”) for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 14, 2023	By:	/s/ Tom Kubota
		Tom Kubota Chief Executive Officer
Date: November 14, 2023	By:	/s/ Kristina Kubota
		Kristina Kubota Chief Financial Officer

XML

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 14, 2023
Document Information Line Items
Entity Registrant Name	PACIFIC HEALTH CARE ORGANIZATION, INC.
Trading Symbol	N/A
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		12,800,000
Amendment Flag	false
Entity Central Index Key	0001138476
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-50009
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0285238
Entity Address, Address Line One	19800 MacArthur Boulevard, Suites 306 & 307
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92612
City Area Code	949
Local Phone Number	721-8272
Title of 12(b) Security	None
Security Exchange Name	NONE
Entity Interactive Data Current	Yes

XML

Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash	$ 2,359,882	$ 2,036,432
Investments	7,769,403	8,748,435
Accounts receivable, net of allowance of $9,302 and $7,807	832,826	934,990
Receivable – other	0	3,000
Prepaid income tax	82,000	0
Prepaid expenses	189,445	175,355
Total current assets	11,233,556	11,898,212
Computer equipment	259,334	256,500
Furniture and fixtures	21,620	20,328
Total property and equipment	280,954	276,828
Less: accumulated depreciation and amortization	(207,075)	(179,423)
Net property and equipment	73,879	97,405
Operating lease right-of-use assets, net	0	50,137
Other assets	7,110	6,602
Total Assets	11,314,545	12,052,356
Current Liabilities
Accounts payable	121,925	263,022
Accrued expenses	314,687	332,551
Income tax payable	193,258	3,132
Dividends payable	109,333	37,000
Operating lease liabilities, current portion	0	39,620
Unearned revenue	37,315	33,544
Total current liabilities	776,518	708,869
Long Term Liabilities
Operating lease liabilities, long term portion	0	10,517
Deferred tax liabilities	15,679	15,679
Total Liabilities	792,197	735,065
Commitments and Contingencies	0	0
Stockholders’ Equity
Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized of which 40,000 shares designated as Series A preferred and 16,000 shares issued and outstanding	16	16
Common stock, $0.001 par value, 800,000,000 shares authorized, 12,800,000 shares issued and outstanding	12,800	12,800
Additional paid-in capital	416,057	416,057
Retained earnings	10,093,475	10,888,418
Total stockholders’ equity	10,522,348	11,317,291
Total Liabilities and Stockholders’ Equity	$ 11,314,545	$ 12,052,356

XML

Consolidated Balance Sheets (Parentheticals) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accounts receivable, allowance (in Dollars)	$ 9,302	$ 7,807
Convertible Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	5,000,000	5,000,000
Convertible Preferred stock, shares issued	16,000	16,000
Convertible Preferred stock, shares outstanding	16,000	16,000
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued	12,800,000	12,800,000
Common stock, outstanding	12,800,000	12,800,000
Common stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock [Member]
Convertible Preferred stock, shares authorized	40,000	40,000

XML

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Revenues	$ 1,376,039	$ 1,453,997	$ 3,987,576	$ 4,281,831
Expenses:
Depreciation and amortization	8,936	9,661	27,652	23,153
Bad debt provision	1,265	(5,520)	2,429	(737)
Consulting fees	56,418	56,148	173,235	166,309
Salaries and wages	638,288	699,026	1,927,044	2,018,638
Professional fees	89,677	76,065	263,880	222,703
Insurance	81,003	79,974	229,599	238,851
Outsource service fees	180,579	156,677	529,861	433,275
Data maintenance	4,524	2,898	69,278	59,400
General and administrative	168,344	112,135	390,019	418,079
Total expenses	1,229,034	1,187,064	3,612,997	3,579,671
Income from operations	147,005	266,933	374,579	702,160
Other income (expense)
Interest income	102,017	0	301,991	0
Total other income (expense)	102,017	0	301,991	0
Income before taxes	249,022	266,933	676,570	702,160
Income tax provision	(69,901)	(74,928)	(189,913)	(197,096)
Net income	$ 179,121	$ 192,005	$ 486,657	$ 505,064
Basic earnings per share:
Earnings per share amount (in Dollars per share)	$ 0.01	$ 0.02	$ 0.04	$ 0.04
Basic common shares outstanding (in Shares)	12,800,000	12,800,000	12,800,000	12,800,000
Fully diluted earnings per share:
Earnings per share amount (in Dollars per share)	$ 0.01	$ 0.01	$ 0.04	$ 0.04
Fully diluted common shares outstanding (in Shares)	12,816,000	12,816,000	12,816,000	12,816,000
HCO [Member]
Revenues:
Revenues	$ 373,280	$ 354,913	$ 945,759	$ 985,192
MPN [Member]
Revenues:
Revenues	132,403	128,297	392,789	422,227
Medical bill review [Member]
Revenues:
Revenues	90,988	99,418	266,030	333,310
Medical case management [Member]
Revenues:
Revenues	292,195	384,657	922,273	1,218,077
Utilization review [Member]
Revenues:
Revenues	451,167	443,049	1,360,998	1,220,941
Other Revenues [Member]
Revenues:
Revenues	$ 36,006	$ 43,663	$ 99,727	$ 102,084

XML

Consolidated Statements of Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 16	$ 12,800	$ 416,057	$ 10,395,532	$ 10,824,405
Balance (in Shares) at Dec. 31, 2021	16,000	12,800,000
Net Income				188,535	188,535
Balance at Mar. 31, 2022	$ 16	$ 12,800	416,057	10,584,067	11,012,940
Balance (in Shares) at Mar. 31, 2022	16,000	12,800,000
Balance at Dec. 31, 2021	$ 16	$ 12,800	416,057	10,395,532	10,824,405
Balance (in Shares) at Dec. 31, 2021	16,000	12,800,000
Net Income					505,064
Balance at Sep. 30, 2022	$ 16	$ 12,800	416,057	10,900,596	11,329,469
Balance (in Shares) at Sep. 30, 2022	16,000	12,800,000
Balance at Mar. 31, 2022	$ 16	$ 12,800	416,057	10,584,067	11,012,940
Balance (in Shares) at Mar. 31, 2022	16,000	12,800,000
Net Income				124,524	124,524
Balance at Jun. 30, 2022	$ 16	$ 12,800	416,057	10,708,591	11,137,464
Balance (in Shares) at Jun. 30, 2022	16,000	12,800,000
Net Income				192,005	192,005
Balance at Sep. 30, 2022	$ 16	$ 12,800	416,057	10,900,596	11,329,469
Balance (in Shares) at Sep. 30, 2022	16,000	12,800,000
Balance at Dec. 31, 2022	$ 16	$ 12,800	416,057	10,888,418	11,317,291
Balance (in Shares) at Dec. 31, 2022	16,000	12,800,000
Net Income				131,109	131,109
Balance at Mar. 31, 2023	$ 16	$ 12,800	416,057	11,019,527	11,448,400
Balance (in Shares) at Mar. 31, 2023	16,000	12,800,000
Balance at Dec. 31, 2022	$ 16	$ 12,800	416,057	10,888,418	11,317,291
Balance (in Shares) at Dec. 31, 2022	16,000	12,800,000
Net Income					486,657
Balance at Sep. 30, 2023	$ 16	$ 12,800	416,057	10,093,475	10,522,348
Balance (in Shares) at Sep. 30, 2023	16,000	12,800,000
Balance at Mar. 31, 2023	$ 16	$ 12,800	416,057	11,019,527	11,448,400
Balance (in Shares) at Mar. 31, 2023	16,000	12,800,000
Net Income				176,427	176,427
Common stock cash dividends paid				(1,280,000)	(1,280,000)
Preferred stock cash dividends paid				(1,600)	(1,600)
Balance at Jun. 30, 2023	$ 16	$ 12,800	416,057	9,914,354	10,343,227
Balance (in Shares) at Jun. 30, 2023	16,000	12,800,000
Net Income				179,121	179,121
Balance at Sep. 30, 2023	$ 16	$ 12,800	$ 416,057	$ 10,093,475	$ 10,522,348
Balance (in Shares) at Sep. 30, 2023	16,000	12,800,000

XML

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Statement of Cash Flows [Abstract]
Net income	$ 486,657	$ 505,064
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	27,652	23,153
Bad debt provision	2,429	(737)
Noncash interest on investments	(126,422)	0
Changes in operating assets and liabilities:
Decrease in accounts receivable	99,735	64,657
Decrease in deferred rent assets	0	10,055
Increase in prepaid expenses	(14,090)	(60,359)
Decrease in income taxes receivable	0	19,779
Decrease in receivable - other	3,000	0
Increase in prepaid income tax	(82,000)	0
(Increase) decrease in other assets	(508)	20,186
(Decrease) increase in accounts payable	(141,097)	44,438
Decrease in accrued expenses	(17,864)	(68,221)
Increase in unearned revenue	3,771	6,979
Increase in income tax payable	190,126	7,316
Net cash provided by operating activities	431,389	572,310
Cash flows from investing activities:
Proceeds from investments	8,748,435	0
Purchase of investments	(7,642,981)	0
Purchase of furniture and office equipment	(4,126)	(17,619)
Net cash provided by (used in) investing activities	1,101,328	(17,619)
Cash flows from financing activities:
Issuance of cash dividend	(1,209,267)	0
Net cash used in financing activities	(1,209,267)	0
Increase in cash	323,450	554,691
Cash at beginning of period	2,036,432	10,085,372
Cash at end of period	2,359,882	10,640,063
Supplemental cash flow information
Interest	0	0
Income taxes	82,000	170,000
Non-cash investing and financing activities:
Dividends payable	$ 72,333	$ 0

XML

BASIS OF FINANCIAL STATEMENT PRESENTATION

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”) and in accordance with accounting principles generally accepted in the United States (“GAAP”). Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted in accordance with GAAP rules and regulations. The information furnished in these unaudited condensed consolidated financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect both the recorded values of assets and liabilities at the date of the condensed consolidated financial statements and the revenues recognized and expenses incurred during the reporting period. These estimates and assumptions affect the Company’s recognition of deferred expenses, bad debts, income taxes, the carrying value of its long-lived assets and its provision for certain contingencies. The reasonableness of these estimates and assumptions is evaluated continually based on a combination of historical and other information that comes to the Company’s attention that may vary its outlook for the future. While management believes the disclosures and information presented are adequate to make the information not misleading, the Company recommends these unaudited condensed consolidated financial statements be read in conjunction with its audited financial statements and notes thereto included in its annual report on Form 10-K for the year ended December 31, 2022. Operating results for the nine-month period ended September 30, 2023, are not necessarily indicative of the results to be expected for the year ending December 31, 2023.

Principles of Consolidation — The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.

Basis of Accounting — The Company uses the accrual method of accounting in accordance with accounting principles generally accepted in the United States for the periods ended September 30, 2023 and 2022.

Revenue Recognition — The Company recognizes revenue in accordance with ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The core principle underlying Topic 606 is that the Company will recognize revenue to represent the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer.

ASC 606 requires the use of a five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. Revenues are generated as services are provided to the customer based on the sales price agreed and collected. The Company recognizes revenue as the time is worked or as units of production are completed, which is when the revenue is earned and realized. Labor costs are recognized as the costs are incurred.

The Company derives its revenue from the sale of services offered through its HCOs, MPNs, medical bill review, medical case management, employee advocate, utilization review, workers’ compensation carve-outs, and Medicare set-aside. These services are billed individually as separate components to our customers. Services from which we generate fees include monthly and/or annual HCO and/or MPN administration, claim and network access, medical bill review, medical case management, employee advocate, utilization review, workers’ compensation carve-outs, and Medicare set-aside.

The Company enters arrangements for bundled managed care, standalone services, or add-on ancillary services which include various units of accounting such as network solutions and patient management, and managed care. Such elements are considered separate units of accounting due to each element having value to the customer on a stand-alone basis and are billed separately. The selling price for each unit of accounting is determined using the contract price. When the Company’s customers purchase several services, the pricing of the service sold is generally the same as if the services were sold on an individual basis. Revenue is recognized as the work is performed in accordance with the Company’s customer contracts. Based upon the nature of the Company’s services, bundled managed care elements are generally delivered in the same accounting period. The Company recognizes revenue for patient management services ratably over the life of the customer contract. Based upon prior experience in managed care, the Company estimates the deferral amount from when the customer’s claim is received to when the customer contract expires. Advance payments from subscribers and billings made in advance are recorded on the balance sheet as deferred revenue.

Accounts Receivable and Bad Debt Allowance – In the normal course of business the Company extends credit to its customers on a short-term basis. Although the credit risk associated with these customers is minimal, the Company routinely reviews its accounts receivable balances and makes provisions for doubtful accounts. The Company ages its receivables by invoice date. Management reviews bad debt reserves quarterly and reserves specific accounts as warranted or sets up a general reserve based on amounts over 90 days past due. When an account is deemed uncollectible, the Company charges off the receivable against the bad debt reserve. A considerable amount of judgment is required in assessing the realization of these receivables including the current creditworthiness of each customer and related aging of the past-due balances, including any billing disputes. To assess the collectability of these receivables, the Company performs ongoing credit evaluations of its customers’ financial condition. Through these evaluations, the Company may become aware of situations where a customer may not be able to meet its financial obligations due to deterioration of its financial viability, credit rating or bankruptcy. The allowance for doubtful accounts is based on the best information available to the Company and is reevaluated and adjusted as additional information is received. The Company evaluates the allowance based on historical write-off experience, the size of the individual customer balances, past-due amounts, and the overall national economy. At September 30, 2023 and December 31, 2022, bad debt reserves of $9,302 and $7,807, respectively, were maintained in a general reserve for certain balances over 90 days past due and for potentially uncollectible accounts.

The percentages of the amounts due from major customers to total accounts receivable as of September 30, 2023 and December 31, 2022, are as follows:

	9/30/2023			12/31/2022
Customer A		34	%		18	%
Customer B		12	%		7	%
Customer C		8	%		24	%

Significant Customers - The Company provides services to insurers, third party administrators, self-administered employers, municipalities, and other industries. The Company is able to provide its full range of services to virtually any size employer in the state of California. Outside the state of California, the Company is able to provide utilization review, medical bill review and medical case management services.

During the periods ended September 30, 2023 and 2022, the Company had three customers, respectively, that individually accounted for more than 10% of its total sales. The following table sets forth the percentages of total sales attributable to those customers during those periods:

	9/30/2023			9/30/2022
Customer A		24	%		28	%
Customer B		10	%		10	%
Customer C		10	%		9	%

Leases - The Company follows the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company elected to exclude from its balance sheet the recognition of leases having a term of 12 months or less. Lease expense is recognized on a straight-line basis over the lease term. See Note 2 for further information regarding the Company’s leases.

XML

OPERATING LEASES

9 Months Ended

Sep. 30, 2023

Disclosure Text Block [Abstract]

Lessee, Operating Leases [Text Block]

NOTE 2 - OPERATING LEASES

On April 1, 2022, the Company moved office locations from 1201 Dove Street, Suite 300 in Newport Beach, California to 19800 MacArthur Boulevard, Suites 306 & 307, in Irvine, California. This lease was to expire as of March 31, 2023, but was renewed on December 10, 2022, for an additional 12-months, with a new expiration of March 31, 2024. The Company elected to exclude from its balance sheet the recognition of leases having a term of 12 months or less.

Lease expenses were $10,714 and $9,903 during the three-month periods ended September 30, 2023 and 2022, respectively; and $31,407 and $19,806 during the nine-month periods ended September 30, 2023 and 2022, respectively.

XML

SHAREHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Equity [Text Block]

NOTE 3 - SHAREHOLDERS’ EQUITY

During the quarter ended June 30, 2023, our board of directors declared a special one-time cash dividend of $0.10 per share on each share of Company common stock outstanding at the record date of June 5, 2023. Pursuant to the rights provided in the Designation of Rights, Privileges and Preferences of Series A Preferred Stock dated December 27, 2019, holders of the Company’s Series A Preferred Stock participated in the dividend payment based on the number of shares of Series A Preferred Stock held on the record date. On the record date, June 5, 2023, we had 12,800,000 shares of common stock and 16,000 shares of Series A Preferred stock issued and outstanding.

As of September 30, 2023, we issued $1,281,600 in dividends with $72,333 of that amount remaining payable. This payable has been accrued and included in the dividends payable on the balance sheet.

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 4 - SUBSEQUENT EVENTS

In accordance with ASC 855-10 Company management reviewed all material events through the date of issuance and has determined that there are no material subsequent events to report.

XML

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation — The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.

Basis of Accounting, Policy [Policy Text Block]

Basis of Accounting — The Company uses the accrual method of accounting in accordance with accounting principles generally accepted in the United States for the periods ended September 30, 2023 and 2022.

Revenue [Policy Text Block]

Revenue Recognition — The Company recognizes revenue in accordance with ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The core principle underlying Topic 606 is that the Company will recognize revenue to represent the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer.

ASC 606 requires the use of a five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. Revenues are generated as services are provided to the customer based on the sales price agreed and collected. The Company recognizes revenue as the time is worked or as units of production are completed, which is when the revenue is earned and realized. Labor costs are recognized as the costs are incurred.

The Company derives its revenue from the sale of services offered through its HCOs, MPNs, medical bill review, medical case management, employee advocate, utilization review, workers’ compensation carve-outs, and Medicare set-aside. These services are billed individually as separate components to our customers. Services from which we generate fees include monthly and/or annual HCO and/or MPN administration, claim and network access, medical bill review, medical case management, employee advocate, utilization review, workers’ compensation carve-outs, and Medicare set-aside.

The Company enters arrangements for bundled managed care, standalone services, or add-on ancillary services which include various units of accounting such as network solutions and patient management, and managed care. Such elements are considered separate units of accounting due to each element having value to the customer on a stand-alone basis and are billed separately. The selling price for each unit of accounting is determined using the contract price. When the Company’s customers purchase several services, the pricing of the service sold is generally the same as if the services were sold on an individual basis. Revenue is recognized as the work is performed in accordance with the Company’s customer contracts. Based upon the nature of the Company’s services, bundled managed care elements are generally delivered in the same accounting period. The Company recognizes revenue for patient management services ratably over the life of the customer contract. Based upon prior experience in managed care, the Company estimates the deferral amount from when the customer’s claim is received to when the customer contract expires. Advance payments from subscribers and billings made in advance are recorded on the balance sheet as deferred revenue.

Receivable [Policy Text Block]

Accounts Receivable and Bad Debt Allowance – In the normal course of business the Company extends credit to its customers on a short-term basis. Although the credit risk associated with these customers is minimal, the Company routinely reviews its accounts receivable balances and makes provisions for doubtful accounts. The Company ages its receivables by invoice date. Management reviews bad debt reserves quarterly and reserves specific accounts as warranted or sets up a general reserve based on amounts over 90 days past due. When an account is deemed uncollectible, the Company charges off the receivable against the bad debt reserve. A considerable amount of judgment is required in assessing the realization of these receivables including the current creditworthiness of each customer and related aging of the past-due balances, including any billing disputes. To assess the collectability of these receivables, the Company performs ongoing credit evaluations of its customers’ financial condition. Through these evaluations, the Company may become aware of situations where a customer may not be able to meet its financial obligations due to deterioration of its financial viability, credit rating or bankruptcy. The allowance for doubtful accounts is based on the best information available to the Company and is reevaluated and adjusted as additional information is received. The Company evaluates the allowance based on historical write-off experience, the size of the individual customer balances, past-due amounts, and the overall national economy. At September 30, 2023 and December 31, 2022, bad debt reserves of $9,302 and $7,807, respectively, were maintained in a general reserve for certain balances over 90 days past due and for potentially uncollectible accounts.

The percentages of the amounts due from major customers to total accounts receivable as of September 30, 2023 and December 31, 2022, are as follows:

	9/30/2023			12/31/2022
Customer A		34	%		18	%
Customer B		12	%		7	%
Customer C		8	%		24	%

Concentration Risk, Customer Risk, Policy [Policy Text Block]

Significant Customers - The Company provides services to insurers, third party administrators, self-administered employers, municipalities, and other industries. The Company is able to provide its full range of services to virtually any size employer in the state of California. Outside the state of California, the Company is able to provide utilization review, medical bill review and medical case management services.

During the periods ended September 30, 2023 and 2022, the Company had three customers, respectively, that individually accounted for more than 10% of its total sales. The following table sets forth the percentages of total sales attributable to those customers during those periods:

	9/30/2023			9/30/2022
Customer A		24	%		28	%
Customer B		10	%		10	%
Customer C		10	%		9	%

Lessee, Leases [Policy Text Block]

Leases - The Company follows the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company elected to exclude from its balance sheet the recognition of leases having a term of 12 months or less. Lease expense is recognized on a straight-line basis over the lease term. See Note 2 for further information regarding the Company’s leases.

XML

BASIS OF FINANCIAL STATEMENT PRESENTATION (Tables)

9 Months Ended

Sep. 30, 2023

Credit Concentration Risk [Member]

BASIS OF FINANCIAL STATEMENT PRESENTATION (Tables) [Line Items]

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

The percentages of the amounts due from major customers to total accounts receivable as of September 30, 2023 and December 31, 2022, are as follows:

	9/30/2023			12/31/2022
Customer A		34	%		18	%
Customer B		12	%		7	%
Customer C		8	%		24	%

Customer Concentration Risk [Member]

BASIS OF FINANCIAL STATEMENT PRESENTATION (Tables) [Line Items]

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

During the periods ended September 30, 2023 and 2022, the Company had three customers, respectively, that individually accounted for more than 10% of its total sales. The following table sets forth the percentages of total sales attributable to those customers during those periods:

	9/30/2023			9/30/2022
Customer A		24	%		28	%
Customer B		10	%		10	%
Customer C		10	%		9	%

XML

BASIS OF FINANCIAL STATEMENT PRESENTATION (Details)	9 Months Ended
	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) [Line Items]
Accounts Receivable, Allowance for Credit Loss	$ 9,302	$ 7,807
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) [Line Items]
Number of Customers	3

XML

BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - Schedules of Concentration of Risk, by Risk Factor - Accounts Receivable [Member] - Customer Concentration Risk [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Customer A [Member]
Concentration Risk [Line Items]
Concentration risk	34.00%	18.00%
Customer B [Member]
Concentration Risk [Line Items]
Concentration risk	12.00%	7.00%
Customer C [Member]
Concentration Risk [Line Items]
Concentration risk	8.00%	24.00%

XML

BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - Schedules of Concentration of Risk, by Risk Factor - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	24.00%	28.00%
Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
Customer C [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	9.00%

XML

OPERATING LEASES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 01, 2022
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Term of Contract					12 months
Operating Lease, Expense	$ 10,714	$ 9,903	$ 31,407	$ 19,806

XML

SHAREHOLDERS' EQUITY (Details) - USD ($)		9 Months Ended
	Jun. 05, 2023	Sep. 30, 2023	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Common Stock, Dividends, Per Share, Declared (in Dollars per share)	$ 0.1
Dividends Payable, Date of Record	Jun. 05, 2023
Common Stock, Shares, Issued	12,800,000	12,800,000	12,800,000
Common Stock, Shares, Outstanding	12,800,000	12,800,000	12,800,000
Preferred Stock, Shares Outstanding	16,000	16,000	16,000
Preferred Stock, Shares Issued	16,000	16,000	16,000
Dividends, Cash (in Dollars)		$ 1,281,600
Dividends Payable, Current (in Dollars)		$ 72,333